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Abstract: 
Substances with the diphenylethylamine nucleus represent a recent 
addition to the product catalog of dissociative agents sold as research 
chemicals on the Internet. Diphenidine, i.e. 1-(1,2-diphenylethyl)piperidine 
(1,2-DEP), is such an example but detailed analytical data are less 
abundant. The present study describes the synthesis of diphenidine and its 
most obvious isomer, 1-(2,2-diphenylethyl)piperidine (2,2-DEP), in order 
to assess the ability to differentiate between them. Preparation and 
characterization were also extended to the two corresponding pyrrolidine 
analogues 1-(1,2-diphenylethyl)- and 1-(2,2-diphenylethyl)pyrrolidine, 
respectively. Analytical characterizations included high-resolution 
electrospray mass spectrometry (HR-ESI-MS), liquid chromatography ESI-
MS/MS, gas chromatography ion trap electron and chemical ionization MS, 
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nuclear magnetic resonance spectroscopy (NMR) and infrared 
spectroscopy. Differentiation between the two isomeric pairs was possible 
under GC-(EI/ CI)-MS conditions and included the formation of distinct 
iminium ions, such as m/z 174 for 1,2-DEP and m/z 98 for 2,2-DEP, 
respectively. The pyrrolidine counterparts demonstrated similar 
phenomena including the expected mass difference of 14 Da due to the 
lack of one methylene unit in the ring. Two samples obtained from an 
Internet vendor provided confirmation that diphenidine was present in both 
samples, concurring with the product label. Finally, it was confirmed that 
diphenidine (30 µM) reduced NMDA-mediated field excitatory postsynaptic 
potentials (NMDA-fEPSPs) to a similar extent to that of ketamine (30 µM) 
when using rat hippocampal slices. The appearance of 1,2- 
diphenylethylamines appears to reflect the exploration of alternatives to 
arylcyclohexylamine-type substances, such as methoxetamine, PCP and 
PCPy-based analogues that also show N-methyl-D-aspartate (NMDA) 
receptor activity as demonstrated here for diphenidine. 
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Running title: Characterization of diphenylethylamines  
 
 
Abstract 
 
Substances with the diphenylethylamine nucleus represent a recent addition to the 
product catalog of dissociative agents sold as research chemicals on the Internet. 
Diphenidine, i.e. 1-(1,2-diphenylethyl)piperidine (1,2-DEP), is such an example but 
detailed analytical data are less abundant. The present study describes the synthesis of 
diphenidine and its most obvious isomer, 1-(2,2-diphenylethyl)piperidine (2,2-DEP), in 
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order to assess the ability to differentiate between them. Preparation and 
characterization were also extended to the two corresponding pyrrolidine analogues 1-
(1,2-diphenylethyl)- and 1-(2,2-diphenylethyl)pyrrolidine, respectively. Analytical 
characterizations included high-resolution electrospray mass spectrometry (HR-ESI-MS), 
liquid chromatography ESI-MS/MS, gas chromatography ion trap electron and chemical 
ionization MS, nuclear magnetic resonance spectroscopy (NMR) and infrared 
spectroscopy. Differentiation between the two isomeric pairs was possible under GC-(EI/ 
CI)-MS conditions and included the formation of distinct iminium ions, such as m/z 174 
for 1,2-DEP and m/z 98 for 2,2-DEP, respectively. The pyrrolidine counterparts 
demonstrated similar phenomena including the expected mass difference of 14 Da due 
to the lack of one methylene unit in the ring. Two samples obtained from an Internet 
vendor provided confirmation that diphenidine was present in both samples, concurring 
with the product label. Finally, it was confirmed that diphenidine (30 µM) reduced NMDA-
mediated field excitatory postsynaptic potentials (NMDA-fEPSPs) to a similar extent to 
that of ketamine (30 µM) when using rat hippocampal slices. The appearance of 1,2- 
diphenylethylamines appears to reflect the exploration of alternatives to 
arylcyclohexylamine-type substances, such as methoxetamine, PCP and PCPy-based 
analogues that also show N-methyl-D-aspartate (NMDA) receptor activity as 
demonstrated here for diphenidine. 
 
 
Keywords: diphenidine; research chemicals; psychoactive; Internet; diarylethylamines; 
isomers; NMDA receptor; PCP; arylcyclohexylamines 
 
 
Introduction 
 
The history of medicinal research and recreational use of so-called dissociative agents is 
closely linked with the two prototypical substances phencyclidine (PCP) and ketamine 
(Figure 1). A central pharmacological feature associated with dissociative agents 
includes the ability to act as a non-competitive antagonist at the N-methyl-D-aspartate 
(NMDA) receptor[1] which also provides access to important leads for drug discovery.[2,3] 
From the perspective of recreational explorations, and what was traditionally thought of 
as clandestine approaches to the preparation of psychoactive material, a close structural 
relationship with known arylcyclohexylamine-type substances, such as PCP, formed a 
key basis.[4-6] While it appeared that PCP-type substances did not attract much attention 
for decades, renewed interest was sparked since the mid-2000s within the recreational 
substance community, which resulted in a re-emergence of a number of PCP-based 
substances predominantly encountered as research chemicals available from online 
vendors.[7]  
 
Methoxetamine (2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one, MXE, Figure 1), 
which may be considered as an invention conceived and developed from within the 
recreational drug community, began to appear more widely in 2010 and attracted some 
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 3
form of popularity amongst users who showed interest in ketamine and 
arylcyclohexylamine-type substances.[7] In the UK, methoxetamine and a range of 
associated substances based on the 1-phenylcyclohexanamine and 2-amino-2-
phenylcyclohexanone template became subject to legislative control in early 2013 using 
a set of generic definitions, thus, impacting on commercial availability of these 
substances.[8]  
 
A feature increasingly observed with a range of research chemicals and so-called new 
psychoactive substances is the expansion from the structurally-based search to the 
exploration of novel structures with equivalent pharmacological targets as banned 
substances.[9] This approach, which commonly includes an evaluation of medicinal 
chemistry and patent literature, has lead to the discovery of structurally diverse 
templates that may be explored for manufacturing and sale on the Internet.  
 
A more recent example of this approach may be found in the 1,2-diarylethylamine class 
which gives rise to a range of substances with diverse properties and may include 
examples such as MT-45 (analgesic activity in mice and also sold as a research 
chemical)[10,11] and AZD6765 (potential antidepressant properties in humans)[12] (Figure 
1). A relatively new addition to the product catalog of online retailers is diphenidine (1) 
(1-(1,2-diphenylethyl)piperidine, 1,2-DEP) (Figure 1). Racemic (1), but also (S)- and (R)-
diphenidine, have been shown to bind to NMDA receptors[13,14] and it has also been 
evaluated for its ability to protect hippocampal neurons from hypoxia-induced cell 
death,[15] although its effect on NMDA receptor-mediated synaptic transmission has not 
been demonstrated. The appearance of diphenidine as a psychoactive research 
chemical was first noticed in 2013.[7] Since analytical details appear to be currently 
absent in the scientific literature, it was decided to synthesize this substance for 
analytical characterization and to confirm its action as an NMDA antagonist at a brain 
synapse. An obvious isomer of diphenidine is the 2,2-diphenylethylamine counterpart 1-
(2,2-diphenylethyl)piperidine (2) (2,2-DEP, Figure 1) and it was also aimed to prepare 
and characterize this candidate in order to assess the ability to differentiate between the 
two substances. In recent years, the unprecedented growth of newly emerging 
psychoactive substances has placed increasing demands on the capability to identify 
and differentiate between closely related analytes (e.g. isomers), thus eliminating the 
possibility of misinterpretation when encountering these substances. Finally, two 
diphenidine samples were also obtained from an Internet vendor to investigate 
consistency with the product label. 
A range of arylcylohexylamines has appeared in recent years on the market and while 
some have been based on the phencyclidine (PCP) template, seen for example in 3-
MeO- or 4-MeO-PCP[16-18], others have included the exploration of pyrrolidine versions, 
such as 3-MeO-PCPy (Figure 1). Although these analogues have been introduced to the 
market, the availability of analytical data has been less abundant.[7,19] For this reason, it 
was decided to prepare the two corresponding pyrrolidine derivatives of these 
diphenylethylamines, i.e. 1-(1,2-diphenylethyl)pyrrolidine (1,2-DEPy) (3) and 1-(2,2-
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 4
diphenylethyl)pyrrolidine (2,2-DEPy) (4), respectively. While detailed investigations 
about the psychoactive properties of all these four substances are currently absent, it 
has been shown that both 1,2-DEP (1) and 1,2-DEPy (3) have been explored for their 
antitussive properties in dogs, which might serve as a typical example for the origin of 
research chemicals within the medicinal chemistry context.[20]  
 
((Please insert Figure 1 about here)) 
Experimental 
 
Materials 
 
All starting materials, reagents and solvents used for synthesis (≥ 96%) were obtained 
from Sigma-Aldrich (St. Louis, MO, USA) Column chromatography was conducted using 
Merck silica gel, grade 9385, 230-400 mesh, 60 Å. Melting point ranges were obtained 
using a DigiMelt A160 SRS melting point apparatus (Stanford Research Systems, USA) 
at a ramp rate of 2 °C/min and are uncorrected. Two samples representing two distinct 
batches of diphenidine (1) were obtained from an online vendor on two different 
occasions. A representative photograph of the purchased product is shown in the 
supplemental information.  
 
Synthesis procedures 
 
1-(1,2-Diphenylethyl)piperidine (1,2-DEP, diphenidine) (1) 
 
A suspension of 1,2- diphenylethanamine (1.2 g, 6.08 mmol), K2CO3 (18.2 mmol) and 1 
mL triethylamine (TEA) in 30 mL dry acetonitrile (4Å molecular sieves) was stirred under 
nitrogen. 1,5-Dibromopentane (1.05 mL, 7.9 mmol) was added and the solution was 
stirred at room temperature under nitrogen over several days. Following completion 
(GC), the reaction was quenched by the addition distilled H2O (dH2O) (300 mL). A few 
mL 2N KOH were added to ensure a basic solution and the solution was extracted with 
ethyl acetate (EtOAc) (3 x 100 mL). The organic phases were pooled and extracted with 
3 x 200 mL 2N aqueous HCl. Aqueous phases were pooled and made basic with KOH 
pellets (pH 12) and extracted with EtOAc (3 × 70 mL). The pooled organic phases were 
dried with anhydrous sodium sulfate and concentrated under vacuum to give amber oil. 
The crude base was purified by flash column chromatography on silica gel with 
hexanes/ethyl acetate (3:1) as mobile phase. The desired fractions were pooled and 
evaporated to give (1) as a colorless oil (1.4 g, 5.28 mmol) in 86.8% yield. This oil 
spontaneously crystallized to a white solid during storage at 0 °C.  
 
The freebase was dissolved in acetone and titrated to pH 2 with concentrated HCl. 
Solvent was evaporated under warm air to give an oily residue. Additional acetone was 
added and evaporated until all residual HCl was driven off to give a white waxy solid. As 
the salt was semi-soluble in acetone, the crystals were washed three times with a 50:50 
mixture of EtOAc and diethyl ether (Et2O). The crystals were dried and crystallized at 
Page 5 of 22
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 5
0 °C from methanol and Et2O. Melting point: 209−210.5 °C with some sublimation (lit.: 
120 °C,[21] 158 °C,[22] 207−208.5 °C,[22] 207−209 °C,[22] 207−209 °C (HCl × H2O,
[14] 
207 °C[20]). 1H NMR (400 MHz, CDCl3, free base) δ 7.37−7.03 (8H, m, Ar-H), 7.04−6.95 
(2H, m, Ar-H), 3.58 (1H, dd, J = 9.4, 5.2 Hz, C1H), 3.30 (1H, dd, J = 13.3, 5.2 Hz, C2H), 
2.99 (1H, dd, J = 13.4, 9.4 Hz, C2H), 2.55−2.29 (4H, m, 2 x CαH2), 1.641.45 (4H, m, 2 x 
CβH2), 1.36 (2H, quintet, J = 5.9 Hz, CγH2). 
13C NMR (100 MHz, CDCl3, free base) δ 
139.98 (quat. Ar-C), 139.44 (quat. Ar-C), 129.35 (2 × Ar-CH), 128.89 (2 × Ar-CH), 
127.81 (2 × Ar-CH), 127.62 (2 × Ar-CH), 126.77 (Ar-CH), 125.59 (Ar-CH), 72.32 (CH, C1), 
51.40 (2 × CH2, Cα), 39.18 (CH2, C2), 26.37 (2 × CH2, Cβ), 24.66 (CH2, Cγ). HR-ESI-MS: 
266.1896 (theory [M+H+], C19H24N
+, 266.1903).  
 
1H NMR (400 MHz, CDCl3, hydrochloride) δ 12.37 (1H, s, NHCl), 7.527.29 (5H, m, Ar-
H), 7.186.97 (5H, m, Ar-H), 4.23 (1H, d, J = 11.6 Hz, C1H), 4.04 (1H, dd, J = 12.8, 3.1 
Hz, C2H), 3.64 (1H, d, J = 10.3 Hz, CαH), 3.54 (1H, d, J = 11.6 Hz, CαH), 3.46 (1H, t, J = 
12.2 Hz, C2H), 2.682.39 (3H, m, CαH2, CβH), 2.31 (1H, q, J = 13.2, 12.2 Hz, CγH) 1.93-
1.76 (3H, m, CβH), 1.27 (1H, q, J = 13.4, 12.4 Hz, CγH).  
13C NMR (100 MHz, CDCl3) δ 
135.77 (quat. Ar-C), 131.01 (quat. Ar-C), 130.23 (2 x Ar-CH), 129.94 (Ar-CH), 129.30 (2 
x Ar-CH), 129.11 (2 x Ar-CH), 128.35 (2 x Ar-CH), 126.75 (Ar-CH), 72.90 (CH, C1), 53.39 
(CH2, Cα), 48.81 (CH2, Cα), 36.75 (CH2, C2), 22.71 (CH2, Cβ), 22.65 (CH2, Cβ), 22.24 
(CH2, Cγ).  
 
1-(2,2-Diphenylethyl)piperidine (2,2-DEP, diphenidine isomer) (2) 
 
This diphenidine isomer was prepared following the same procedure using 2,2-
diphenylethanamine (1.2 g, 6.08 mmol). The free base product (80.7% yield) was 
converted into the hydrochloride salt as described above. The crystals were 
recrystallized twice from methanol and Et2O at 0 °C to give a hygroscopic white solid 
(1.3 g, 4.31 mmol). Melting point: 144.5−145.5 °C (lit.: 140 °C,[23] 145−147 °C,[24] 
130−132 °C[25]). 1H NMR (400 MHz, CDCl3, free base) δ 7.30−7.21 (8H, m, Ar-H), 
7.19−7.13 (2H, m, Ar-H), 4.21 (1H, t, J = 7.3 Hz, C2H), 2.93 (2H, d, J = 7.3 Hz, C1H2), 
2.39 (4H, t, J = 5.4 Hz, 2 × CαH2), 1.46 (4H, quintet, J = 5.5 Hz, 2 × CβH2), 1.37 (2H, 
quintet, J = 5.4 Hz, CγH2). 
13C NMR (100 MHz, CDCl3, free base) δ 144.40 (2 × quat. Ar-
C), 128.22 (6 × Ar-CH), 126.01 (2 × Ar-CH), 64.53 (CH2, C1), 54.85 (2 × CH2, Cα), 48.89 
(CH, C2), 25.99 (2 × CH2, Cβ), 24.43 (CH2, Cγ) HR-ESI-MS: 266.1895 (theory [M+H+]: 
C19H24N
+, 266.1903). 
 
1-(1,2-Diphenylethyl)pyrrolidine (1,2-DEPy) (3) 
 
This diphenidine isomer was prepared following the same procedure using 1,2-
diphenylethanamine (1.2 g, 6.08 mmol) and 1,5-dibrombutane (1 mL, 7.9 mmol) in 
58.9% yield. The freebase product was converted into the hydrochloride salt as 
described above to give a white solid.  The hydrochloride salt gave a melting point of 
205.5−207.8 °C (lit.: 212 °C[20,26]). 1H NMR (400 MHz, CDCl3, free base) δ 7.24−7.08 (8H, 
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m, Ar-H), 6.91−6.83 (2H, m, Ar-H), 3.36 (1H, dd, J = 13.3, 4.3 Hz, C2H), 3.30 (1H, dd, J 
= 9.9, 4.3 Hz, C1H), 2.96 (1H, dd, J = 13.3, 9.9 Hz, C2H), 2.64 (2H, m, CαH2), 2.45 (2H, 
m, CαH2), 1.77 (4H, quintet, J = 3.3 Hz, 2 × CβH2). 
13C NMR (100 MHz, CDCl3, free base) 
δ 142.34 (quat. Ar-C), 139.13 (quat. Ar-C), 129.48 (2 × Ar-CH), 128.29 (2 × Ar-CH), 
127.80 (2 × Ar-CH), 127.75 (2 × Ar-CH), 126.80 (Ar-CH), 125.66 (Ar-CH), 73.31 (CH, 
C1), 53.0 (2 × CH2, Cα), 42.96 (CH2, C2), 23.35 (2 × CH2, Cβ). HR-ESI-MS: 252.1740 
(theory [M+H+]: C18H22N
+, 252.1747). 
  
1-(2,2-Diphenylethyl)pyrrolidine (2,2-DEPy (4) 
 
This isomer was prepared as described above using 2,2-diphenylethanamine (1.2 g, 
6.08 mmol), which gave a yellow oil (85.0% yield). The hydrochloride salt was 
recrystallized three times at 0 °C from methanol and Et2O which provided a melting point 
of 174.3−176 °C (lit.: 174−175 °C[27]). 1H NMR (400 MHz, CDCl3, free base) δ 7.33−7.25 
(8H, m, Ar-H), 7.24−7.16 (2H, m, Ar-H), 4.22 (1H, t, J = 7.1 Hz, C2H), 3.14 (2H, d, J = 7.4 
Hz, C1H2), 2.51 (4H, t, J = 6.1 Hz, 2 × CαH2), 1.72 (2H, quintet, J = 3.1 Hz, CβH2). 
13C 
NMR (100 MHz, CDCl3, free base) δ 144.04 (2 × quat. Ar-C), 128.36 (4 × Ar-CH), 
128.03 (4 × Ar-CH), 126.20 (2 × Ar-CH), 61.74 (CH2, C1), 54.55 (2 × CH2, Cα), 50.87 
(CH, C2), 23.50 (2 × CH2, Cβ). HR-ESI-MS: 252.1740 (theory [M+H
+]: C18H22N
+, 
252.1747).  
 
Instrumentation 
 
Gas chromatography ion trap mass spectrometry 
 
GC ion trap MS data were obtained in electron (EI) and chemical ionization (CI) mode 
(scan range m/z 41–m/z 500) using a Varian 450-GC gas chromatograph coupled to a 
Varian 220-MS ion trap mass spectrometer. A Varian 8400 autosampler was employed 
with a CP-1177 injector (275 ºC) in split mode (1:50). Data acquisition was performed 
with the MS Data Review function of the Workstation software, version 6.91. Transfer 
line, manifold and ion trap temperatures were set at 310, 80, and 220 ºC, respectively. 
The liquid CI reagent was HPLC grade methanol. CI ionization parameters (0.4 s/scan): 
CI storage level 19.0 m/z; ejection amplitude 15.0 m/z; background mass 55 m/z; 
maximum ionization time 2000 µs; maximum reaction time 40 ms; target TIC 5000 
counts. A 30 m × 0.25 mm (0.25 µm film thickness) Agilent J&W VF-5ms GC column 
(Stockport, UK) was employed for separation. The starting temperature was set at 50 ºC 
and held for 1 min. The temperature then increased at 20 ºC/min to 300 ºC and held 
constant for 5.00 minutes to give a total run time of 18.50 min. Samples were prepared 
by dissolving the HCl salt in methanol at a concentration of 0.5 mg/mL. 
 
Liquid chromatography electrospray triple quadrupole mass spectrometry 
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LC-MS/MS experiments were performed on a Waters (Micromass) Quattro Premier 
(Waters Ltd., Manchester, UK) with an ESI source and interfaced to a Waters Alliance 
2695 HPLC system operated under Masslynx v 4.1 software. Separation was obtained 
using a Waters Sunfire™ C8 column (3.5 µm; 4.6 mm × 50 mm) held at 30 °C and 
water: methanol gradient elution with a flow rate of 0.8 mL/min. Solvent A consisted of 
10 mM aqueous ammonium formate, 0.1% formic acid and Solvent B consisted of 
methanol with 10 mM ammonium formate, 0.1% formic acid. The gradient elution 
method was: 0–2 min: 98% A and 2% B; 2–18 min: gradient to 32% A and 68% B; 18-19 
min: returned to 98% A and 2% B then equilibrated for 11 min. Samples were dissolved 
in mobile phase (50% A: 50% B) at a concentration of 10 µg/mL and the injection volume 
was 5 µL. 
 
Tandem mass spectra (MS/MS) were collected in positive ion mode by multiple reaction 
monitoring (MRM). The optimized source conditions were as follows: capillary 3.12 kV, 
cone 28 V, rf lens 0.1 V, source temperature 100 °C, desolvation temperature 400 °C, 
cone gas flow 50 L/hr, desolvation gas flow 500 L/hr. The collision gas was argon (0.3 
mL/min flow). The protonated precursor ion for piperidines (1) and (2) was set at m/z 266 
and four product ions were collected, i.e. at m/z 181, m/z 166, m/z 103 and m/z 86 using 
collision energies of 20 eV, 28 eV, 35 eV and 48 eV respectively. The protonated 
precursor ion for pyrrolidines (3) and (4) was at m/z 252 and four product ions were 
collected, i.e. at m/z 181, m/z 166, m/z 103 and m/z 72 using collision energy values of 
20 eV, 28 eV, 35 eV and 48 eV respectively. Dwell time for each channel was 0.05 s. 
Interchannel delay was 0.02 s. Product ion spectra were obtained from direct infusion 
(10 µL/mL; concentration 1 µg/mL). The standard MS/MS settings were applied, 
however, masses were collected between m/z 45 and m/z 200; collision voltage 28 eV; 
desolvation temperature 200°C; desolvation gas flow 200 L/hr.  
 
High-resolution electrospray mass spectrometry  
HR-ESI mass spectra for the substances obtained from synthesis and test purchases 
were recorded by direct injection into a LTQ Orbitrap Discovery (Thermo Fisher, Bremen, 
Germany). Samples were dissolved in acetonitrile/water (1:1, containing 0.1% formic 
acid) and infused at a rate of 5 µL/min. Full accurate high-resolution (30000) mass scans 
were performed in positive electrospray mode. Measured accurate masses were within ± 
5 ppm of the theoretical masses. The following conditions were used: drying gas (N2) 10 
L/min, capillary temperature 310  °C, spray voltage 4 V, capillary voltage 22 V and tube 
lens 77 V.  
 
Nuclear magnetic resonance spectroscopy  
 
1H (400 MHz) and 13C NMR spectra (100 MHz) were obtained in CDCl3 solutions (100% 
and 99.96% D, 0.03% (v/v) TMS) on a Bruker Ultrashield 400 plus spectrometer with a 5 
mm BBO S1 (Z gradient plus) probe at 24 °C.  Internal chemical shift references were 
TMS (δ = 0.00 ppm) and solvent (δ = 77.0 ppm). Samples were run as the free bases at 
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a concentration of approximately 20 mg/mL. Aliphatic chemical shifts were assigned 
using 1-D and 2-D heteronuclear experiments. 
 
Electrophysiology 
 
Four to six week old male and female Wistar rats (Charles River, UK) were euthanized 
by cervical dislocation, in accordance with the United Kingdom Animals (Scientific 
Procedures) Act 1986. The brains were rapidly removed and placed into artificial 
cerebrospinal fluid (aCSF: 124 mM NaCl, 3 mM KCl, 26 mM NaHCO3, 1.4 mM NaH2PO4, 
1 mM MgSO4, 10 mM D-glucose, 2 mM CaCl2), continuously oxygenated with 95% O2 
and 5% CO2. Parasagittal hippocampal slices (400 µM) were prepared, and experiments 
carried out in submerged conditions and at a temperature of 28−30°C, as described 
previously.[28] Briefly, field excitatory postsynaptic potentials (fEPSPs) were evoked at 
0.03 Hz using a bipolar stimulating electrode, and recorded using glass micropipettes 
pulled to a resistance of 3-6 MΩ and filled with 3 M NaCl. Both electrodes were 
positioned in stratum radiatum of area CA1, and NMDA-fEPSPs were isolated by 
addition of picrotoxin (50 µM), CGP 55845 hydrochloride (1 µM) and NBQX (10 µM) to 
the perfusate, in order to block GABA-A, GABA-B and AMPA/kainate receptors, 
respectively. Responses were measured and recorded online using WinLTP.[29]  
 
Results and discussion 
 
The preparation of diphenidine (1), its 2,2-DEP isomer (2) and their pyrrolidine 
counterparts (3) and (4) was based on the use of the commercially available primary 
amines 1,2- and 2,2-diphenylethanamine, respectively, followed by reaction with the 
corresponding 1,5-dibromoalkane (Figure 2). This procedure was also employed by 
Berger et al. for the preparation of diphenidine and its single enantiomers [14] and it 
previously provided convenient access to the preparation of PCP and PCPy 
analogues.[19] The synthesis of diphenidine was reported first in 1924 and was based on 
a modified Bruylanys reaction between benzylmagnesium bromide and the 
corresponding α-arylamino nitrile.[21] A number of additional synthetic routes to 
diphenidine have been described and include modified Mannich-type reactions 
employing benzyl bromide, piperidine and benzaldehyde[30] and gold-catalyzed 
hydroamination of diphenylacetylene with piperidine.[31] 
 
 ((Please insert Figure 2 about here)) 
 
Mass spectrometry and chromatography 
 
The electron- and chemical ionization (EI/CI) ion trap (IT) mass spectra and their gas 
chromatography (GC) retention times for all four diphenylethylamines (1) – (4) are 
summarized in Figure 3A−H. Representative GC traces are shown as supplemental 
data to indicate separation of isomers. EI-induced fragmentation of all four substances 
gave rise to a base peak, which was consistent with an iminium species following α-
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cleavage (Figure 4). In case of diphenidine (1), for example, base peak formation was 
observed at m/z 174 (Figures 3A and 4A) while the pyrrolidine counterpart fragmented to 
the equivalent ion at m/z 160 due to the mass difference of 14 Da (Figure 3C). The 
significance of this particular base peak was that it would allow for the ability to 
differentiate between some isomers in cases where one of the phenyl rings showed 
additional substituents. In other words, substituents present on the phenyl ring attached 
to the 1-position ethylamine chain would be expected to shift the m/z value to larger m/z 
values beyond m/z 174. Another main observation made with the 1-(1,2-diphenylethyl) 
substituted compounds (1) and (3) was the presence of the tropylium species at m/z 91 
(Figures 3A and 3C) which, given their difference in structure, were not detected with 
their 1-(2,2-diphenylethyl) isomers (2) and (4) (Figures 3E and 3G). The significance of 
the tropylium ion would, however, become of additional interest if there was a need to 
verify the presence of a substituted phenyl ring located at the 2-position of the 
ethylamine chain, thus, giving a tropylium ion at higher m/z values. 
 
While implementation of EI resulted in very low abundance of the molecular ions, a 
protonated molecule was conveniently detected when operating under GC-CI-IT-MS 
conditions, which aided confirmation of the corresponding molecular mass values 
(Figures 3B, 3D, 3F and 3H). Additional dissociation of the protonated molecule provided 
further information, which included the detection of an even-electron species associated 
with the primary amine, i.e. m/z 86 for diphenidine and m/z 72 for 1,2-DEPy, respectively 
(Figures 3B, 3D and 4B). This was consistent with previous CI-IT-MS studies of a range 
of PCP and PCPy analogues where the piperidine and pyrrolidine fragments have also 
been detected.[19]  
 
A mass spectral comparison between the 1-(1,2-diphenylethyl) and 1-(2,2-diphenylethyl) 
compounds (1)/(3) and (2)/(4) highlighted that differentiation between isomers was 
possible under EI- and CI conditions. For example, the diphenidine isomer (2) gave an 
iminium base peak at m/z 98 instead of m/z 174 observed for diphenidine (Figures 3E 
and 4). A suggested fragmentation pathway for 2,2-DEP (2) is shown in Figures 4C−F 
and equivalent mechanisms may have been involved in the fragmentation behaviour of 
the pyrrolidine counterpart 2,2-DEPy (4) considering the associated mass difference of 
14 Da. GC analysis also indicated that it was possible to distinguish between the two 
pairs of constitutional isomers.  
 
((Please insert Figures 3 and 4 about here)) 
 
Mass spectra and ion ratios (five most abundant species) for compounds (1) – (4) 
obtained from liquid chromatography electrospray triple quadrupole mass spectrometry 
analysis (LC-ESI-MS/MS) are shown in Figure 5. Characteristic fragments observed with 
all four analytes included m/z 181, 179, 166, 165 and 103, respectively, and a suggested 
fragmentation pathway is shown in Figure 6. The implementation of ESI-MS/MS did not 
reveal differential fragmentations between isomers (1)/(2) and (3)/(4) as observed under 
EI and CI conditions (Figure 3). However, a difference in relative abundance observed 
Page 10 of 22
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 10
for the detection of protonated piperidine (m/z 86) and protonated pyrrolidine (m/z 72) 
was noted which might be useful when considering the use of distinct ion ratios (Figure 
5). Further studies, including the implementation of different ESI-based instrumentation, 
might be indicated to assess robustness. 
 
((Please insert Figures 5 and 6 about here)) 
 
Nuclear magnetic resonance spectroscopy  
  
The C1 proton 
1H chemical shifts of diphenidine (1) and its pyrrolidine analogue (3) 
appeared as a doublet of doublets split by the two non-equivalent C2 vicinal protons. The 
C2 protons are diastereotopic relative to the C1 proton, leading to two separate doublets 
of doublets for the C2 
1H chemical shifts (Figure 7). This reflected both geminal (2JHH) 
coupling to each other and vicinal (3JHH) coupling with the C1 proton. The C2 
1H chemical 
shifts were separated by ~0.2−0.3 ppm. The 2JHH coupling constants were equivalent 
(~13 Hz) between the upfield and downfield C2 
1H chemical shifts although the 3JHH 
coupling constants were distinct between the upfield and downfield C2 chemical shifts 
~9.5 vs. ~4.5 Hz, respectively. Presumably, this was due to the different dihedral angles 
between each of the C2 protons and the C1 proton about the C1−C2 bond.   
 
The 1H and 13C spectra of (1), (R)-(1) and (S)-(1) free base and the hydrochloride salt 
have been previously published[14,31] and the results obtained in the present study were 
largely consistent. Two “additional” 13C chemical shifts were reported with the 
hydrochloride salt.[14] When acquiring the NMR spectra for the HCl salt of diphenidine, a 
similar observation was made and 2-D HMQC analysis carried out here suggested that 
Cα and Cβ carbons appeared as four 
13C chemical shifts as opposed to two. The free 
base, however, did not reveal distinct signals. Conformation alteration resulting from 
protonation and a resulting non-equivalence of both Cα and Cβ carbons may have been 
involved in the observed effect.  The 1H and 13C spectra of (3) free base were consistent 
with data published previously.[31] For convenience the 1H and 13C assignments for the 
assigned aliphatic shifts for compounds (1) – (4) and the HCl salt of (1) are presented in 
in the supplementary information.  
 
((Please insert Figure 7 about here)) 
 
The C1 
1H chemical shifts appeared as a doublet due to 3JHH coupling to the single C2 
proton. The C1 resonance of 1,2-diphenylethylamines (1) and (3) were observed upfield 
relative to the 2,2-diphenylethylamines counterparts (2) and (4). The C2 
1H chemical 
shifts gave a triplet (J ~7.3 Hz) due to 3JHH coupling to the two equivalent C1 protons.  
The C1 
13C chemical shifts for the 1,2-diphenylethylamines (1) and (3) were observed 
further downfield when compared to their 2,2-diphenylethylamine isomers (2) and (4) 
due to the electron-withdrawing effect of the phenyl substituent at C1. This ∆C1 was 
5.6−11.6 ppm. Correspondingly, in the 2,2-diphenylethylamines, the C2 
13C chemical 
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shift was further downfield from their 1,2-diphenylethylamine counterparts due to the 
deshielding effect of the diphenyl rings (∆C2 = ~8−10 ppm). The ring-related methylene 
groups Cα, Cβ and Cγ showed similar 
13C chemical shifts for all four compounds. In all 
cases, the Cα chemical shift was furthest downfield due to its proximity to the basic 
amine nitrogen, followed by the Cβ chemical shift and Cγ which appeared to be most 
upfield in (1) and (3).    
 
Confirmation of NMDA receptor antagonism 
Hippocampal slices were pharmacologically treated to isolate NMDA receptor mediated 
events, confirmed by blocking with the selective NMDA antagonist, d-2-amino-5-
phosphonopentanoate (D-AP5; Figure 8). On such slices, diphenidine (30 µM) reduced 
NMDA-fEPSPs to 32 ± 6% of baseline (Figure 8A). This was similar to the effect of 
ketamine (30 µM), which reduced NMDA-fEPSPs to 35 ± 2% of baseline (Figure 8B). 
The onset of antagonism by diphenidine was slower than that of ketamine and 
reminiscent of the slower kinetics of NMDA antagonism by MK-801 on brain slices.[32] 
Although beyond the scope of this study, more complex intracellular recordings with 
varying membrane potentials are required to calculate the on and off kinetics in order  to 
give more accurate biophysical potencies. Further in vivo recordings would be needed to 
provide systemic potencies.  
 
((Please insert Figure 8 about here)) 
The analytical characterization and synthesis of diphenidine (1) and its three analogues 
(2)–(4) confirmed that the two products obtained from an online retailer were consistent 
with diphenidine as indicated on the product label (see supplementary information for 
additional data). Differentiation between the two pairs of isomers was observed when 
comparing NMR, EI- and CI-MS spectra and chromatographic retention times. 
Diphenidine was introduced to the UK market in 2013 and it appears to be psychoactive 
in man,[7] most likely due to the antagonism of NMDA receptor-mediated synaptic events 
as demonstrated here. However the overall psychopharmacological and physiological 
activity of diphenidine in humans may involve additional molecular targets including non-
NMDA receptors, transport proteins and enzymes. A shift to diarylethylamines might 
represent an example where the expected pharmacological rather than structural 
similarities may have impacted on its exploration as a research chemical. In the UK, 
recently introduced legislative measures[8] precludes the commercial availability of 
methoxetamine and related derivatives which might add to the attempt to explore 
potential alternatives for the research chemicals market that are not controlled. Indeed, 
2-methoxyphenidine, i.e. 1-(1-(2-methoxyphenyl)-2-phenylethyl)piperidine, has also 
recently appeared as a commercially available research chemical and detailed 
investigations, including their differentiation from their corresponding isomers, are 
currently underway. 
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Conclusion 
 
1-(1,2-Diphenylethyl)piperidine (diphenidine) and related substances have recently 
appeared as research chemicals. Detailed analytical data, which are relevant for forensic 
and clinical work, appear to be currently absent. The preparation and in-depth 
characterization of diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl 
isomers were aimed to close this gap and it was also revealed that differentiation 
between isomers was feasible. Diphenidine reduced NMDA-mediated field excitatory 
postsynaptic potentials similar to ketamine when using rat hippocampal slices and 
further studies on the potential similarity to other dissociative agents are warranted.  
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Figure 1. Diphenidine (1) has recently appeared as a psychoactive research chemical. Substances (1) – (4) 
were subject to synthesis and characterization in the present study.  
186x179mm (300 x 300 DPI)  
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Figure 2. Synthesis scheme used for the preparation of (1) – (4) in the presence of potassium carbonate 
and triethylamine (TEA). The primary 1,2- or 2,2-diphenylethanamines were reacted with 1,5-
dibromopentane or 1,5-dibromobutane to give the desired products.  
110x69mm (300 x 300 DPI)  
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Figure 3. A — H: Gas chromatography retention times, electron ionization and chemical ionization ion trap 
mass spectra (EI/CI-IT-MS) observed for compounds of (1) – (4). The differentiation between isomers was 
possible.  
144x96mm (300 x 300 DPI)  
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Figure 4. Suggested fragmentation pathways for diphenidine (1) as a representative example under electron 
ionization and chemical ionization ion trap mass spectrometry conditions (see Figure 3 for spectra).  
266x328mm (300 x 300 DPI)  
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Figure 5. Liquid chromatography retention times, ion ratios and electrospray ionization triple quadrupole 
mass spectra obtained for substances (1) – (4).  
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Figure 6. Suggested fragmentation pathways for diphenidine (1) and its pyrrolidine analogue (3) as a 
representative example under ESI-MS/MS conditions (see Figure 5 for spectra).  
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Figure 7. A partial Heteronuclear Multiple Quantum Coherence (HMQC) NMR spectrum of diphenidine (1).  
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Figure 8. Effects of ketamine and diphenidine (1) on NMDA-fEPSPs in rat hippocampal slices. Pooled data 
and representative traces showing the reduction of NMDA-fEPSPs induced by A: a 90 minute application of 
diphenidine (30 µM); and B: a 60 minute application of ketamine (30 µM). D-AP5 (100 µM) application at 
the end of experiments induced a near-complete depression of responses. Drug effects were quantified and 
results are shown in the bar graphs on the right.  
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